TMBIM4 and cardiomyopathy: The disruption of cytoskeletal and sarcomeric proteins by a decrease in expression or anomalous arrangement could underlie cardiomyopathies and heart failure, representing a potential mechanism by which drugs inhibiting S1R jeopardize cardiac integrity and contractility (Sequeira et al., 2014).